Jujube (Ziziphus Jujuba Mill.) is an excellent medicinal and edible plant owing to its high nutritional and health-promoting properties. As an important bioactive component, Z. Jujuba polysaccharides have aroused wide attention due to their various pharmacological activities, including anti-inflammatory, immunomodulatory, anti-oxidant, anti-tumor, anti-viral, regulating gut microbiota, hepatoprotective effects and prebiotic activity, and so on. This review highlights the advancements in the extraction methods, structural characteristics, structural elucidation, and functional analysis of polysaccharides derived from Jujube fruits over the past decade, aiming to provide valuable insights for future development and commercialization of Jujube fruits polysaccharides.
26 January 2024 in Naunyn-Schmiedeberg's Archives of Pharmacology
Osteoarthritis (OA) is the most common type of arthritis and affects more than 240 million people worldwide; the most frequently affected areas are the hips, knees, feet, and hands. OA pathophysiology is multifactorial, involving genetic, developmental, metabolic, traumatic, and inflammation factors. Therefore, treatments able to address several path mechanisms can help control OA. Network pharmacology is developing as a next-generation research strategy to shift the paradigm of drug discovery from “one drug, one target” to “multi-component, multi-target”. In this paper, network pharmacology is employed to investigate the potential role of Paeoniae Radix Alba (PRA) in the treatment of OA. PRA is a natural product known for its protective effects against OA, which has recently drawn attention because of its ability to provide physiological benefits with fewer toxic effects. This review highlights the anti-inflammatory properties of PRA in treating OA. PRA can be used alone or in combination with conventional therapies to enhance their effectiveness and reduce side effects. The study also demonstrates the use of network pharmacology as a cost-effective and time-saving method for predicting therapeutic targets of PRA in OA treatment.
9 October 2024 in Russian Journal of Bioorganic Chemistry
Objective: The objective of this study was to design and synthesize novel apigenin derivatives and evaluate their antitumor activities against NSCLC cells. Methods: A series of apigenin derivatives were synthesized and their antiproliferative effects were evaluated against the NSCLC cell line A549. The most promising compounds were identified based on their antitumor activities. Their safety was confirmed by testing them on the normal human lung cell line Beas-2B. The mechanisms of their antitumor activities were investigated by inducing apoptosis in A549 cells and inhibiting Akt protein phosphorylation. The physicochemical and ADME properties of these compounds were also predicted to evaluate their potential as PI3K inhibitors for NSCLC therapy. Results and Discussion: Compounds (Va) and (VIa) exhibited suitable antitumor activities against A549 cells, with no significant toxicity towards Beas-2B cells. They were capable of inducing apoptosis in A549 cells and inhibiting Akt protein phosphorylation, which preliminarily revealed their mechanisms for antitumor activities in vitro. The predictions of physicochemical and ADME properties showed that compound (VIa) would be a potent PI3K inhibitor for NSCLC therapy in the future. Conclusions: This study has successfully designed and synthesized apigenin derivatives with antitumor activities for NSCLC therapy. Compounds (Va) and (VIa) exhibited suitable antitumor activities with low toxicity and promising mechanisms of action. The physicochemical and ADME properties of compound (VIa) suggest its potential as a potent PI3K inhibitor for NSCLC therapy in the future. These findings provide valuable insights for the development of novel therapeutic agents against NSCLC.